This article only represents the author's own views.
A couple of recent acquisitions are proving strong tonic for Viva Biotech Holdings (1873.HK), a globally-focused Chinese provider of third-party pharmaceutical services for other drug makers.
The company posted a more than fivefold surge in first-half revenues after completing two key purchases that not only added a major new business area but also lifted Viva Biotech back to profitability, according to its latest results posted last week.
您已閱讀8%（494字），剩余92%（5488字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。